

This is a translated copy of the original

Annual and consolidated financial statements for

H100 Group AB

556578-5622

Fiscal year

2024-05-01 - 2025-04-30

H100

Board of Directors' Report	1
Income statement - Group	4
Balance sheet - Group	5
Cash flow statement - Group	7
Income statement - Mother	8
Balance sheet - Mother	9
Cash Flow Statement - Moder	11
Note	12
Signatures	22

Board of Directors' Report

The Board of Directors of H100 Group AB (publ), 556578-5622, presents the following Annual Report and Consolidated Financial Statements for the financial year 2024-05-01 - 2025-04-30.

Activities

Nature and focus of the activities

In 2024, H100 Group AB, formerly eBlitz Group AB, conducted a strategic review of the company's operations and concluded that the company's operations at the time, but the focus on investments in smaller companies and advice on this, did not have the conditions to develop well, based on the market situation, the company's size and liquidity. Therefore, a decision was made that the best thing for the company and its shareholders was to change the company's business direction, through the acquisition of new operations. When the opportunity arose to through a so-called reverse acquisition, Healty to 100 AS, this led to this happening and the acquisition was completed on April 7, 2025, when the company also changed its name to H100 Group AB.

H100 Group AB is now a listed company in Sweden, focused on building a comprehensive digital health ecosystem through strategic acquisitions and AI-driven automation. The company's platform integrates seamlessly with existing healthcare providers, allowing them to improve service delivery, increase efficiency, and scale operations. H100 Group provides the infrastructure and back-office support for health and longevity service providers, enabling them to focus on customer care while we handle the rest.

The goal is to develop the business and grow both organically and through the acquisition of suitable businesses.

The investment portfolio that eBlitz Group had at the time of the acquisition remains in H100 Group and the intention is to divest it gradually in order to maximize value for the company and its shareholders.

Significant events during the financial

year-On August 26, 2024, eBlitz Group entered into a letter of intent to acquire Healty to 100 AS.

-In January 2025, Patric Sjölund will take over as acting CEO.

-On January 16, eBlitz Group enters into an agreement to acquire all shares in Healty to 100 AS.

-In February 2025, NGM approves the relisting, as a result of the reverse acquisition, of H100 Group AB.

-On March 7, 2025, an Extraordinary General Meeting approves the reverse acquisition of Healty to 100 AS-The

acquisition of Healty to 100 AS will be completed on April 7, 2025 and Sander Andersen will take over as the new CEO of the Group.

-From April 23, 2025, the company's shares are traded on NGM under the name H100.

-In April, H100 Group enters into an agreement with Epivity Health and Livity as users of the company's e-health platform.

The company is headquartered in Stockholm.

Information on owners who have more than ten per cent of the number of shares or votes in the company

The number of shares in H100 Group AB amounted to 117,089,006 as of April 30, 2024. There is only one

class of shares in the company and the quota value is SEK 0.1 per share.

The H100 Group AB share has been traded on NGM Nordic SME since October 18, 2019. H100 Group AB

is traded under the ticker "H100" and the share has the following ISIN code: SE0009580756.

The number of shareholders was approximately 1,950 according to Euroclear. Below is a list of the company's largest shareholders.

Name	Number of shares	Holding
Middelborg Invest AS	27 445 726	23,4%
Growthiogen Invest AS	19 180 225	16,4%
E-Nerd AS	13 787 614	11,8%
Modiola AS	13 764 072	11,8%
Crafoord Capital Partners AB	5 211 567	4,5%
Avanza Pension	4 012 290	3,4%
Race Ventures Scandinavia AB	2 200 000	1,9%
OEBC Holdin Ltd	2 200 000	1,9%
Nordnet Pension	1 468 488	1,3%
Other	27 819 024	23,8%
Completely	117 089 006	100%

Fair overview of developments

Group

	2024/2025	2023/2024	2022/2023	Amount in kr 2021/2022
Net sales	3 044 692	1 499 378	2 445 018	15 032 724
Operating income	-5 206 409	-7 848 828	-3 636 455	3 020 253
Profit after financial items	-16 721 126	-9 767 786	-5 885 452	2 675 804
Return on Total Capital %	-14,7	-36,1	-16	9
Return on Equity %	-15,7	-38	-22	9
Balance sheet total	113 333 734	27 041 800	36 673 487	29 942 528
Equity ratio %	93,7	95,1	95	97
Average number of employees	1	1	1	1

Mother

	2024/2025	2023/2024	2022/2023	Amount in kr 2021/2022
Net sales	2 009 510	1 499 379	2 445 018	15 032 724
Operating income	-2 140 949	-7 825 456	-3 635 060	3 020 253
Profit after financial items	-13 647 451	-9 744 470	-5 884 060	2 675 804
Return on Total Capital %	-12,2	-35,6	-15,9	8,8
Return on Equity %	-12,4	-37,9	-16,6	9,2
Balance sheet total	111 529 746	27 336 258	36 969 805	30 241 757
Equity ratio %	98,6	94,2	94	96
Average number of employees	1	1	1	1

Changes in equity - Group

	<i>Share capital</i>	<i>Other capital contributed</i>	<i>Retained earnings, including profit for the year</i>
Opening balance	1 854 441	49 581 821	-25 713 295
Nyemission	9 854 460	88 690 137	
Expenses related to the issue		-1 322 259	
Profit for the year			-16 721 126
Closing balance	11 708 901	136 949 699	-42 434 421

Changes in Equity - Mother

	<i>Share capital</i>	<i>Reserve fund</i>	<i>Free premium fund</i>	<i>Retained earnings</i>
Opening balance	1 854 441	812 011	0	32 818 749
To be carried forward				-9 744 470
Nyemission	9 854 460		88 690 137	
Expenses related to the issue			-626 308	
Closing balance	11 708 901	812 011	88 063 829	23 074 279
				<i>Profit for the year</i>
Opening balance				-9 744 470
To be carried forward				9 744 470
Profit for the year				-13 647 451
Closing balance				-13 647 451

Appropriation of earnings

	Amount in kr
<i>The following funds are at the disposal of the Annual General Meeting</i>	
Free share premium reserve	88 063 828
Retained earnings	23 074 280
Profit for the year	-13 647 451
Funds to dispose of	97 490 657
<i>The Board proposes that the funds be allocated as follows</i>	
To be carried forward	97 490 657
Summa	97 490 657

Income statement - Group

<i>Amount in kr</i>	<i>Not</i>	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Operating income, inventory changes, etc.			
Net sales	3	3 044 692	1 499 378
Other operating income		158 662	11 495
Total operating income, changes in inventory, etc.		3 203 354	1 510 873
Operating expenses			
Merchandise		-2 659 085	-6 191 508
Other external costs	4	-3 110 535	-1 247 545
Personnel costs	5	-1 128 918	-1 766 160
Depreciation of tangible and intangible fixed assets		-1 214 939	-150 000
Other operating expenses		-296 286	-4 488
Total operating expenses		-8 409 763	-9 359 701
Operating income		-5 206 409	-7 848 828
Profit from financial items			
Profit from other securities that are non-current assets		-11 505 797	-1 938 294
Other interest income and similar profit and loss items		0	21 285
Interest expenses and similar profit and loss items		-8 920	-1 949
Total profit from financial items		-11 514 717	-1 918 958
Profit after financial items		-16 721 126	-9 767 786
Profit before tax		-16 721 126	-9 767 786
Profit for the year		-16 721 126	-9 767 786
Attributable to parent company shareholders		-16 721 126	-9 767 786

Balance sheet - Group

<i>Amount in kr</i>	<i>Not</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
ASSETS			
Fixed assets			
Intangible fixed assets			
Concessions, patents, licenses, trademarks and similar rights	6	600 000	750 000
Goodwill	7	83 421 093	0
Total intangible fixed assets		84 021 093	750 000
Property, plant and equipment			
Inventory, tools and installations		28 929	0
Total property, plant and equipment		28 929	0
Financial fixed assets			
Other long-term securities holdings	9	11 750 020	23 440 354
Total financial fixed assets		11 750 020	23 440 354
Total fixed assets		95 800 042	24 190 354
Current assets			
Inventories, etc.			
Stocks of securities		0	1 807 606
Total inventories, etc.		0	1 807 606
Current receivables			
Accounts receivable		660 247	0
Current tax asset		0	3 698
Other receivables		1 362 309	137 033
Deferred expenses and accrued income	10	0	59 657
Total current receivables		2 022 556	200 388
Cash and bank			
Cash and bank		15 511 136	843 452
Total cash and bank		15 511 136	843 452
Total current assets		17 533 692	2 851 446
TOTAL ASSETS		113 333 734	27 041 800

Balance sheet - Group

<i>Amount in kr</i>	<i>Not</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
EQUITY AND LIABILITIES			
Equity			
Action capital		11 708 901	1 854 441
Other capital contributed		136 949 699	49 581 821
Retained earnings, including profit for the year		-42 434 421	-25 713 295
Equity attributable to owners of the parent company		106 224 179	25 722 967
Total equity		106 224 179	25 722 967
Current liabilities			
Accounts payable		4 307 198	58 463
Current tax liabilities		240 599	0
Other liabilities		2 504 758	173 788
Accrued expenses and deferred income	11	57 000	1 086 582
Total current liabilities		7 109 555	1 318 833
TOTAL EQUITY AND LIABILITIES		113 333 734	27 041 800

Cash flow statement - Group

<i>Amount in kr</i>	<i>Not</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
Ongoing operations			
Input value of ongoing operations			
Profit after financial items		-16 721 126	-9 767 786
Adjustment for items that are not included in the cash flow		11 517 051	5 693 231
Income tax paid			58 190
Cash flow from operating activities before changes in working capital		-5 204 075	-4 016 365
Cash flow from changes in working capital			
Increase/decrease in inventories and work in progress		1 807 606	1 274 113
Change in operating receivables			
Increase/decrease in trade receivables			5 625
Increase/decrease in other current receivables		39 663	4 877
Increase/decrease in operating receivables		1 847 269	1 284 615
Change in operating liabilities			
Increase/decrease in accounts payable		641 294	-62 594
Increase/decrease in other current liabilities		-712 958	205 037
Increase/decrease in operating liabilities		-71 664	142 443
Cash flow from operating activities		-3 428 470	-2 589 307
Investment			
Acquisition of shares in Group companies		18 101 838	
Acquisition of other financial non-current assets			-374 764
Divestment of other financial non-current assets			1 220 108
Cash flow from investing activities		18 101 838	845 344
Financing activities			
Nyemission			-6 344
Amortization of debt		-5 684	
Cash flow from financing operations		-5 684	-6 344
Cash flow for the year		14 667 684	-1 750 307
Cash and cash equivalents at the beginning of the year		843 452	2 593 759
Cash and cash equivalents at year-end		15 511 136	843 452

Income statement - Mother

<i>Amount in kr</i>	<i>Not</i>	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Operating income, inventory changes, etc.			
Net sales	3	2 009 510	1 499 379
Other operating income		158 662	11 495
Total operating income, changes in inventory, etc.		2 168 172	1 510 874
Operating expenses			
Merchandise		-2 029 378	-6 191 508
Other external costs	4	-1 216 085	-1 224 174
Personnel costs	5	-913 658	-1 766 160
Depreciation of tangible and intangible fixed assets		-150 000	-150 000
Other operating expenses		0	-4 488
Total operating expenses		-4 309 121	-9 336 330
Operating income		-2 140 949	-7 825 456
Profit from financial items			
Profit from other financial fixed assets		-11 496 272	-1 938 295
Other interest income and similar profit and loss items		-9 562	21 225
Interest expenses and similar profit and loss items		-668	-1 944
Total profit from financial items		-11 506 502	-1 919 014
Profit after financial items		-13 647 451	-9 744 470
Profit before tax		-13 647 451	-9 744 470
Profit for the year		-13 647 451	-9 744 470

Balance sheet - Mother

<i>Amount in kr</i>	<i>Not</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
ASSETS			
Fixed assets			
Intangible fixed assets			
Concessions, patents, licenses, trademarks and similar rights	6	600 000	750 000
Total intangible fixed assets		600 000	750 000
Financial fixed assets			
Shares in Group companies	8	98 894 597	300 000
Other long-term securities holdings	9	11 750 020	23 440 354
Total financial fixed assets		110 644 617	23 740 354
Total fixed assets		111 244 617	24 490 354
Current assets			
Inventories, etc.			
Stock Securities		0	1 807 606
Total inventories, etc.		0	1 807 606
Current receivables			
Current tax asset		0	3 698
Other receivables		232 200	134 832
Deferred expenses and accrued income	10	0	59 657
Total current receivables		232 200	198 187
Cash and bank			
Cash and bank		52 929	840 111
Total cash and bank		52 929	840 111
Total current assets		285 129	2 845 904
TOTAL ASSETS		111 529 746	27 336 258

Balance sheet - Mother

<i>Amount in kr</i>	<i>Not</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Action capital		11 708 901	1 854 441
Reserve Fund		812 011	812 011
Total restricted equity		12 520 912	2 666 452
Free equity			
Free share premium reserve		88 063 829	0
Retained earnings		23 074 280	32 818 750
Profit for the year		-13 647 451	-9 744 470
Total unrestricted equity		97 490 658	23 074 280
Total equity		110 011 570	25 740 732
Long-term liabilities			
Liabilities to Group companies	13	278 744	0
Total long-term liabilities		278 744	0
Current liabilities			
Accounts payable		699 755	58 463
Liabilities to Group companies		0	284 428
Current tax liabilities		25 124	0
Other liabilities		464 553	173 054
Accrued expenses and deferred income	11	50 000	1 079 581
Total current liabilities		1 239 432	1 595 526
TOTAL EQUITY AND LIABILITIES		111 529 746	27 336 258

Cash Flow Statement - Moder

<i>Amount in kr</i>	<i>Not</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
Ongoing operations			
Input value of ongoing operations			
Profit after financial items		-13 647 451	-9 744 470
Adjustment for items that are not included in the cash flow		11 095 998	5 693 231
Income tax paid			58 190
Cash flow from operating activities before changes in working capital		-2 551 453	-3 993 049
Cash flow from changes in working capital			
Increase/decrease in inventories and work in progress		1 807 606	1 274 113
Change in operating receivables			
Increase/decrease in trade receivables			5 625
Increase/decrease in other current receivables		34 013	4 449
Increase/decrease in operating receivables		1 841 619	1 284 187
Change in operating liabilities			
Increase/decrease in accounts payable		641 294	-62 594
Increase/decrease in other current liabilities		-712 958	178 938
Increase/decrease in operating liabilities		-71 664	116 344
Cash flow from operating activities		-781 498	-2 592 518
Investment			
Acquisition of other financial non-current assets			-374 764
Divestment of other financial non-current assets			1 220 108
Cash flow from investing activities		0	845 344
Financing activities			
Nyemission			-6 344
Amortization of debt		-5 684	
Cash flow from financing operations		-5 684	-6 344
Cash flow for the year		-787 182	-1 753 518
Cash and cash equivalents at the beginning of the year		840 111	2 593 629
Cash and cash equivalents at year-end		52 929	840 111

Note

Amount in SEK unless otherwise stated.

Note 1 Accounting and valuation principles

Accounting and valuation principles

The Annual Report has been prepared in accordance with the Annual Accounts Act and the Swedish Accounting Standards Board's general guidelines BFNAR 2012:1 Annual Report and Consolidated Financial Statements (K3).v The accounting principles are unchanged compared with the previous year.

The Parent Company and the Group apply the same accounting principles unless otherwise stated below.

The

Parent Company has previously carried out external service assignments on both current and fixed accounts, which have been reported as attributable to a service assignment performed and as income as work is performed and materials are delivered or consumed. In the acquisition of Healthy to 100 AS, the parent company has no external service assignments.

Fixed assets

Intangible and property, plant and equipment are recognised at cost less accumulated depreciation according to plan and any impairment losses. Depreciation takes place on a straight-line basis over the estimated useful life. The depreciation period for internally accumulated intangible fixed assets amounts to 10 years. The Board of Directors has chosen a 10-year depreciation plan taking into account the strategic life of the asset. In the Group, the 5-year depreciation rate for goodwill is applied.

Financial instruments

Financial instruments are reported in accordance with the rules in Chapter 12 of Chapter 3 and the Group classifies its financial assets into the following categories:

-Financial assets and liabilities held for trading-Investments held mature-Loan receivables and trade receivables-Financial assets available for sale-Other financial liabilities.

The classification depends on the purpose of the acquisition of the financial asset. The purpose is determined by management at the first reporting session.

A financial asset or liability must be recognised on the balance sheet when the company has become part of the contractual terms and conditions of the financial instrument. Purchases and sales of financial assets are reported on the business day, the date on which the Group commits to buy or sell the asset.

Financial assets are first recognised at fair value plus transaction costs, which applies to all financial assets that are not recognised at fair value through profit or loss. Financial assets measured at fair value through the income statement are recognised at fair value for the first time, while transaction costs attributable to transactions are recognised in the income statement.

Loans and trade receivables as well as investments held to maturity are recognised after the acquisition date at amortised cost using the effective interest rate method. Trade receivables are measured at amortised cost using the effective interest rate method, less any provision for depreciation.

Financial assets available for sale and financial assets and liabilities held for trading are recognised at fair value after the date of acquisition. Gains and losses due to changes in fair value are recognised as follows:

- Financial assets measured at fair value via the income statement – in the income statement as financial income or expenses.
- Financial assets available for sale - in fair value fund

Financial assets or liabilities held for trading

This category refers to financial assets or liabilities identified at the time of initial recognition as assets or liabilities held for trading. These are valued at fair value on an ongoing basis and the change in value is recognised in the income statement. The main assets in the category consist of shares and participations in listed and unlisted companies, but not participations in subsidiaries or associated companies.

Loans and trade receivables

Loans and trade receivables are trade receivables, current receivables with fixed payments and fixed maturities. Receivables are reported as current assets, with the exception of items maturing more than 12 months after the balance sheet date, which are classified as non-current assets.

Loan liabilities and trade payables

Loan liabilities and trade payables are recognised at cost after deduction of transaction costs. If the reported amount differs from the amount to be repaid at maturity, the difference is accrued as interest expense over the term of the loan using the instrument's effective interest rate. This means that the reported amount and the amount to be repaid correspond at the due date.

Impairment testing of financial non-current assets

At each balance sheet date, the Company assesses whether there is any indication of impairment in any of the financial non-current assets. Impairment is made if the decline in value is deemed to be permanent. The impairment requirement is assessed individually for shares and participations and other individual financial fixed assets that are material.

Shares and participations in associated companies and subsidiaries

Shares and participations in associated companies and subsidiaries are reported at cost after deduction of any impairment charges. The acquisition value includes the purchase price paid for the shares and acquisition costs. Any capital contributions and group contributions are added to the cost as they arise. Dividends from subsidiaries are reported as income.

Other long-term securities holdings

Posten consists of shares. The holdings were acquired to be held on a long-term basis, but as a result of changes in the company's operations, the intention is to divest the shares. Assets included in the item are reported at fair value.

Other liabilities (Loan liabilities and accounts payable)

The concept of other liabilities includes - Loan liabilities and accounts payable.

Fair

value of financial instruments traded on an active market and where there are observable market transactions is based on quoted market prices. The market price on the balance sheet date is the last market price set.

For financial instruments that have no observable market transactions, i.e. unlisted financial instruments such as shares and convertibles, a fair value valuation is made. The company's management conducts an overall assessment to determine which valuation method is best suited for each instrument. As the company's holdings of unlisted shares are intended to be divested, special consideration has been given to the potential sale price, where the company is evaluating various possibilities. The price obtained or observed has also been taken into account if it is recently

or most recently an orderly transaction (new issue, sale, etc.) has been carried out in the unlisted instrument, unlisted, between market participants so that the price can be considered representative of fair value.

If no external representative transaction is recorded during the year-end period, the holding is evaluated on the basis of an internal valuation by the company's management, based on the latest current acquisition cost, book value or transaction value, in relation to a current valuation of the financial instrument.

Tax

liabilities/receivables are valued at what the company assesses to be paid to or received from the tax agency. The assessment is made in accordance with the tax rules and tax rates that have been decided or that have been announced and will be determined with a high degree of certainty. Deferred tax relating to future tax effects is not recognised in the income statements and balance sheets.

Cash flow statement

The cash flow statement is prepared according to the indirect method. The reported cash flow only includes transactions that have resulted in incoming or outgoing payments.

In addition to cash and cash equivalents, the company classifies as cash and cash equivalents available to banks and other credit institutions as well as short-term liquid investments listed on a marketplace with a maturity of less than three months from the date of acquisition. Changes in blocked funds are reported in investment activities.

Key figure definitions

Equity

ratio Equity and untaxed reserves (less deferred tax) in relation to the balance sheet total.

Return on total capital

Profit before deduction of interest expenses in relation to the balance sheet total.

Return on equity

Profit after financial items in relation to equity and untaxed reserves (less deferred tax).

Note 2 Estimates and estimates

Through the acquisition of Healthy to 100 AS, goodwill of SEK 83,421,093 has arisen in the Group. The assessment is that this value, based on the acquired company, its cash flows and position in the market, is well justified. The assessment has been made that goodwill should be amortized over 5 years.

Note 3 Distribution of net sales

Group and parent company

Net sales by business line

<i>Activity</i>	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
SecuritiesSecurities	3 044 692	-1 499 379
Summa	3 044 692	-1 499 379

Note 4 Remuneration to auditors

Group

<i>Auditor and audit firm</i>	<i>Type of assignment</i>	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Allians Revision & Redovisning ABAllians Revision & Redovisning AB	Audit assignments	57 000	69 628
Summa		57 000	69 628

Mother

<i>Auditor and audit firm</i>	<i>Type of assignment</i>	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Allians Revision & Redovisning ABAllians Revision & Redovisning AB	Audit assignments	50 000	69 628
Summa		50 000	69 628

Not 5 Personal

Group

Average number of employees

	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Men	1	1
Average number of employees	1	1

Salaries and other remuneration

	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
The Board of Directors and the CEO	815 043	1 278 300
Summa	815 043	1 278 300

Social security costs including pension costs

	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Pension costs		
The Board of Directors and the CEO	203 613	457 052
Total pension costs	203 613	457 052
Summa	203 613	457 052

Mother

Average number of employees

	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Men	1	1
Average number of employees	1	1

Salaries and other remuneration

	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
The Board of Directors and the CEO	815 043	1 278 300
Summa	815 043	1 278 300

Social security costs including pension costs

	<i>2024-05-01 - 2025-04-30</i>	<i>2023-05-01 - 2024-04-30</i>
Pension costs		
The Board of Directors and the CEO	203 613	457 052
Total pension costs	203 613	457 052
Summa	203 613	457 052

Note 6 Concessions, patents, licences, trademarks and similar rights

Group

	<i>2025-04-30</i>	<i>2024-04-30</i>
Opening acquisition values	1 500 000	1 500 000
Closing costs	1 500 000	1 500 000
Input depreciation	-750 000	-600 000
Changes in depreciation		
Depreciation for the year	-150 000	-150 000
Closing depreciation	-900 000	-750 000
Carrying amount	600 000	750 000

Mother

	<i>2025-04-30</i>	<i>2024-04-30</i>
Opening acquisition values	1 500 000	1 500 000
Closing costs	1 500 000	1 500 000
Input depreciation	-750 000	-600 000
Changes in depreciation		
Depreciation for the year	-150 000	-150 000
Closing depreciation	-900 000	-750 000
Carrying amount	600 000	750 000

Not 7 Goodwill

Group

	2025-04-30	2024-04-30
Changes in acquisition values		
Business combinations	84 485 846	
Closing costs	84 485 846	
Changes in impairment losses		
Depreciation for the year	-1 064 753	
Closing depreciation	-1 064 753	
Carrying amount	83 421 093	

Note to note

Through the acquisition of Healthy to 100 AS, goodwill of SEK 83,421,093 has arisen in the Group after depreciation. The assessment is that this value, based on the acquired company, its cash flows and position in the market, is well justified. The assessment has been made that goodwill should be amortized over 5 years.

Note 8 Participations in Group companies

<i>Refers to the parent company</i>	2025-04-30	2024-04-30
Opening acquisition values	300 000	300 000
Changes in acquisition values		
Purchase	98 544 597	
Closing costs	98 844 597	300 000
Changes in revaluations		
Revaluations for the year	50 000	
Outgoing revaluations	50 000	0
Carrying amount	98 894 597	300 000

Holdings of shares in Group companies

<i>Company name</i>	<i>Org.nr</i>	<i>Seat</i>	<i>Capital share %</i>	<i>Carrying amount</i>
Healty to 100 AS	932736758	Oslo	100	98 544 597
eBlitz AB	556579-2909	Stockholm	100	150 000
Unlisted Services AB	556634-8206	Stockholm	100	100 000
Unlisted Listan AB	556618-2250	Stockholm	100	100 000

Note 9 Other long-term securities holdings

Group

	2025-04-30	2024-04-30
Opening acquisition values	20 894 951	25 991 007
Changes in acquisition values		
Purchase		374 764
Sales		-1 827 332
Reclassifications		-3 643 488
Closing costs	20 894 951	20 894 951
Input revaluations	6 737 956	5 421 943
Changes in revaluations		
Revaluations for the year		4 133 092
Write-downs for the year on the amount written up	-6 737 956	-2 817 079
Outgoing revaluations	0	6 737 956
Opening impairment charges	-4 192 553	-1 584 021
Change in impairment losses		
Reversed impairment charges		453 703
Impairment losses for the year	-4 951 678	-3 062 235
Closing impairment charges	-9 144 231	-4 192 553
Carrying amount	11 750 720	23 440 354

Mother

	2025-04-30	2024-04-30
Opening acquisition values	20 894 951	25 991 007
Changes in acquisition values		
Purchase		374 764
Sales		-1 827 332
Reclassifications		-3 643 488
Closing costs	20 894 951	20 894 951
Input revaluations	6 737 956	5 421 943
Changes in revaluations		
Revaluations for the year		4 133 092
Write-downs for the year on the amount written up	-6 737 956	-2 817 079
Outgoing revaluations	0	6 737 956
Opening impairment charges	-4 192 553	-1 584 021
Change in impairment losses		
Reversed impairment charges		453 703
Impairment losses for the year	-4 951 678	-3 062 235
Closing impairment charges	-9 144 231	-4 192 553
Carrying amount	11 750 720	23 440 354

Note 10 Deferred expenses and accrued income

Group and Parent Company

	2025-04-30	2024-04-30
Prepaid rental costs		9 000
Other deferred expenses and accrued income		
<i>Type of interim item</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
Other itemsOther items		50 657
Summa		59 657

Note 11 Accrued expenses and deferred income

Group

	2025-04-30	2024-04-30
Accrued holiday pay		492 660
Accrued social security contributions		203 983
Other accrued expenses and deferred income		
<i>Type of interim item</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
RevisionRevision	57 000	151 235
Accrued Board FeesAccrued Board Fees		238 704
Summa	57 000	1 086 582

Mother

Other accrued expenses and deferred income		
<i>Type of interim item</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
Accrued vacationAccrued vacation		492 660
Accrued Board FeesAccrued Board Fees		238 704
Accrued social security contributionsAccrued social security contributions		203 893
RevisionRevision	50 000	69 628
Other itemsOther items		74 697
Summa	50 000	1 079 582

Note 12 Pledged collateral

Group and Parent Company

Collateral provided on behalf of the Group

For own liabilities and provisions

<i>Type of debt or provision</i>	<i>Type of security</i>	<i>2025-04-30</i>	<i>2024-04-30</i>
	Business mortgages	500 000	500 000
Total collateral pledged		500 000	500 000

Note 13 Related party transactions

The loans from the subsidiaries are interest-free and have no fixed repayment period.

Note 14 Significant events after the end of the financial year

- On May 16, H100 announces the launch of its global health initiative.
- The first bitcoin investment is made on May 22.
- On May 25, H100 secures SEK 21 million in a convertible loan facility led by Adam Back.
- H100 Group enters into an introductory agreement with Finpeers SA.
- On 3 June, preliminary figures for the year 2024/2025 will be released.
- H100 Group secures an additional SEK 21 million in convertible loan from Adam Back, with the right to invest up to an additional SEK 128 million with a planned total size of SEK 277 million.
- On June 9, H100 Group secures SEK 28.4 million through a convertible loan and share issue.
- On June 11, the year-end report for 2024/2025 will be released.
- The company secures SEK 101 million in financing in the form of convertible loans.
- On June 11, the company resolves on a directed share issue of a total of approximately SEK 71.5 million-On June 12, it is announced that investors have requested conversion of convertible loan tranche 2-4.
- The company will sign additional financing within the framework of convertible tranches 2-4 on June 14.
- On June 16, additional financing of SEK 150 million will be signed with investor Adam Back.
- Tranche 5 of the convertible loan is requested to be converted by investors on June 16.
- On June 19, the company secures additional financing within the framework of the convertible bond tranche 5.

Further information on significant events after the end of the financial year is available on the company's website www.h100.group.

Signatures

Sander Andersen

Sander Andersen Date
Chief executive officer

Joakim Mikael Dahl

Joakim Mikael Dahl Date
Board member

Jonatan Bendtsen
Raknes

Jonatan Date
Bendtsen Raknes
Chairperson

Kristian Gjertsen
Lundkvist

Kristian Gjertsen Date
Lundkvist
Board member

Our auditor's report has been submitted to

Allians Revision & Redovisning AB

Per Hjalmar Lindblom

Per Hjalmar Lindblom